Invitae Corporation (0JDB.L)
| Previous close | 0.5914 |
| Open | 0.5700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.5611 - 0.6049 |
| 52-week range | 0.4477 - 2.9220 |
| Volume | |
| Avg. volume | 54,264 |
| Market cap | 517,623 |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0560 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Motley FoolBetter Growth Stock: CRISPR Therapeutics vs. Invitae
Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. You'll find a lot of these candidates in the area of biotech, and two possibilities that come to mind right now are gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) and genetic-testing specialist Invitae (NYSE: NVTA). Which is the better growth stock to buy now?
Insider MonkeyInvitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript
Invitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript November 8, 2023 Invitae Corporation beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.3. Operator: Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today’s call. We will have a […]
